Expanding Clinical Footprint VivoSight Dx Pro is already trusted in clinical practices across Europe, USA, Asia, and Australia with about 90 systems in active clinical use in Germany alone, indicating strong market demand and potential for expansion in oncology dermatology and cosmetic clinics.

Validated Diagnostic Platform Over 800 peer‑reviewed publications and more than 200,000 patient scans establish VivoSight as the most extensively validated OCT platform in clinical dermatology, signaling high credibility for sales pitches to hospitals, universities, and research labs.

AI‑assisted Workflow Integrated VivoAID AI module enhances image interpretation and workflow speed, offering a compelling value proposition for clinics seeking to improve diagnostic efficiency and patient throughput.

Diversified Use Cases Beyond dermatology, VivoSight supports academic skin research, cosmetics R&D, microneedle patch development, wound healing assessment, and aesthetic treatment monitoring, presenting cross‑sell opportunities to pharma, biotech, and cosmetics partners.

Growth Signals Current revenue range and substantial funding indicate a growth trajectory; opportunities exist to align with potential distributors, raise pilot program awareness, and pursue strategic partnerships with larger medtech firms seeking OCT capabilities in dermatology.